Difference between revisions of "Alisertib (MLN-8237)"
Jump to navigation
Jump to search
m |
m |
||
| Line 11: | Line 11: | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| − | [[Category: | + | [[Category:Aurora kinase inhibitors]] |
[[Category:Aggressive Non-Hodgkin lymphoma medications]] | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
Revision as of 23:16, 15 November 2014
Mechanism of action
Aurora A kinase (AAK) inhibitor
Preliminary results
Aggressive Non-Hodgkin lymphoma
Mantle cell lymphoma
- Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. link to original article PubMed